Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

[Background] Talquetamab is the first GPRC5D × CD3 bispecific antibody approved for relapsed or refractory multiple myeloma. In phase 1 of the MonumenTAL-1 study, initial results of subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks showed preliminary clinical activity. We de...

Descripción completa

Detalles Bibliográficos
Autores: Chari, Ajai, Touzeau, Cyrille, Schinke, Carolina, Minnema, Monique, Berdeja, Jesús G., Oriol, Albert, Donk, Niels W. C. J. van de, Rodríguez-Otero, Paula, Morillo, Daniel, Martínez-Chamorro, Carmen, Mateos, Maria Victoria, Costa, Luciano J., Caers, Jo, Rasche, Leo, Krishnan, Amrita, Ye, Jing Christine, Karlin, Lionel, Lipe, Brea, Vishwamitra, Deeksha, Skerget, Sheri, Moreau, Philippe
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:dnet:digitalcsic_::aaa6cbc34d8ec68546c8341ac3495f85
Acceso en línea:http://hdl.handle.net/10261/426444
Access Level:acceso abierto
Descripción
Sumario:[Background] Talquetamab is the first GPRC5D × CD3 bispecific antibody approved for relapsed or refractory multiple myeloma. In phase 1 of the MonumenTAL-1 study, initial results of subcutaneous talquetamab 0·4 mg/kg once a week and 0·8 mg/kg every 2 weeks showed preliminary clinical activity. We describe safety and activity results in patients treated with talquetamab, including patients who had received previous T-cell redirection therapy (TCR). This post-hoc analysis was done with more mature median follow-up to evaluate duration of response in patients treated with talquetamab 0·8 mg/kg every 2 weeks.

Similares en LA Referencia